Compare · AZN vs DCOY
AZN vs DCOY
Side-by-side comparison of AstraZeneca PLC (AZN) and Decoy Therapeutics Inc. (DCOY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and DCOY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $243.37B, about 134584.7x DCOY ($1.8M).
- Over the past year, AZN is down 16.7% and DCOY is down 95.1% - AZN leads by 78.4 points.
- AZN has been more active in the news (28 items in the past 4 weeks vs 10 for DCOY).
- AZN has more recent analyst coverage (25 ratings vs 1 for DCOY).
- Company
- AstraZeneca PLC
- Decoy Therapeutics Inc.
- Price
- $156.93-1.95%
- $2.80+5.66%
- Market cap
- $243.37B
- $1.8M
- 1M return
- -3.08%
- -32.69%
- 1Y return
- -16.66%
- -95.06%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2015
- News (4w)
- 28
- 10
- Recent ratings
- 25
- 1
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Latest AZN
- RBC Capital Mkts initiated coverage on AstraZeneca
- SEC Form 6-K filed by AstraZeneca PLC
- IMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancer
- Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials
- SEC Form 6-K filed by AstraZeneca PLC
- ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
Latest DCOY
- Director Lieber Jonathan I was granted 2,000 shares, increasing direct ownership by 100,000% to 2,002 units (SEC Form 4)
- Chief Business Officer Marschel Peter Klaus was granted 3,900 shares (SEC Form 4)
- Chief Executive Officer Pierce Frederick Ii was granted 33,455 shares, increasing direct ownership by 2,409% to 34,844 units (SEC Form 4)
- Chief Financial Officer Rosenblum Mark J was granted 9,682 shares, increasing direct ownership by 576% to 11,363 units (SEC Form 4)
- Chief Scientific Officer Hibner Barbara Louise was granted 4,216 shares (SEC Form 4)
- Director Hanish Arnold C was granted 3,000 shares, increasing direct ownership by 718% to 3,418 units (SEC Form 4)
- Director Lammers Paul was granted 2,000 shares, increasing direct ownership by 200,000% to 2,001 units (SEC Form 4)
- Director Burleson Tess was granted 2,000 shares, increasing direct ownership by 100,000% to 2,002 units (SEC Form 4)
- Director Mcvicar William K. was granted 3,000 shares, increasing direct ownership by 150,000% to 3,002 units (SEC Form 4)
- Director Gauthier Patricia G. was granted 2,000 shares (SEC Form 4)